Podcasts about fda

PhenoNet Cleared By FDA To Begin Phase 3 Trial Of Inhaled Alzheimer's Drug PhenoNet has received FDA clearance to begin a Phase 3 trial of PHENOGENE-1A, an inhaled formulation of cromolyn sodium, an asthma drug with decades of safety data. Unlike most Alzheimer's therapies, which target only APOE4 gene carriers, this ~648-person trial stratifies both carriers and non-carriers by genotype, testing whether reducing amyloid aggregation, inflammation, and microglial dysfunction can benefit a broader Alzheimer's population than current treatments reach. Host Dave Asprey explains why this genotype-inclusive design challenges the field's narrow focus on APOE4 carriers, and what it means for families with Alzheimer's history who don't carry the gene. Sources: https://www.morningstar.com/news/business-wire/20260813649121/phenonet-cleared-by-fda-to-begin-phase-3-trial-of-inhaled-phenogene-1a-in-early-alzheimers-disease https://www.businesswire.com/news/home/20260813649121/en/ https://www.phenonet.us ~~~University Of Zurich Researchers Discover The Adult Brain Can Repair Itself Better Than Believed Researchers at the University of Zurich identified a population of "regenerative astrocytes" in living mouse brains that repair damaged tissue through a previously unknown mechanism: dividing cells send newly formed nuclei traveling across long cellular extensions to repopulate injured regions and rebuild the astrocyte network. The discovery overturns the long-standing assumption that adult brains have limited capacity to replace lost astrocytes after injury or autoimmune disease. Host Dave Asprey unpacks why this finding reframes brain injury recovery as something the body may already be equipped to handle, and what the newly identified genetic pathways could mean for future regenerative therapies. Sources: https://www.news.uzh.ch/en/articles/media/2026/regenerative-astrocytes.html https://www.sciencedaily.com/releases/2026/08/260812015158.htm https://www.eurekalert.org/news-releases/1139114 https://www.nature.com/articles/s41593-026-02354-5 ~~~Sheep's Wool-Derived Keratin Outperforms Collagen In Bone Regeneration Study Researchers at King's College London developed a keratin scaffold from sheep's wool, a farming industry waste product, and tested it against collagen, the current gold standard, in rats with non-healing skull defects. While collagen produced more total bone volume, the keratin scaffold generated bone that was more structurally organized and closer to natural bone architecture, while remaining stable and integrating cleanly with surrounding tissue. Host Dave Asprey explains why bone quality, not just quantity, matters for weight-bearing repair, and why a cheaper, more sustainable material outperforming the standard is a bigger deal than it sounds. Sources: https://medicalxpress.com/news/2026-04-scientists-wool-bone-material.html https://www.sciencedaily.com/releases/2026/08/260812015210.htm https://www.ivanhoe.com/news_flash/scientists-turn-sheeps-wool-into-a-material-that-helps-regrow-bone-click-here/ ~~~Oral GLP-1 Pill Aleniglipron Shows 12% Weight Loss In Phase 2b Trial Structure Therapeutics' oral small-molecule GLP-1 receptor agonist, aleniglipron, produced up to 12.1% weight loss at 36 weeks in a 230-person Phase 2b trial, with no apparent plateau and continued loss to 16% in the open-label extension, putting an oral pill in the same efficacy range as injectable GLP-1 drugs like Wegovy and Ozempic. Host Dave Asprey weighs the compliance advantage of an oral option against his ongoing concerns about muscle loss, rebound weight gain, and the fact that GLP-1 drugs treat a symptom rather than the underlying metabolic cause. Sources: https://pubmed.ncbi.nlm.nih.gov/42249138/ https://www.nature.com/articles/s41591-026-04476-6 https://ir.structuretx.com/news-releases/news-release-details/structure-therapeutics-announces-publication-nature-medicine/ https://www.fiercebiotech.com/biotech/structure-touts-16-weight-loss-aleniglipron-highest-efficacy-oral-glp-1 ~~~Study Finds 150 Minutes Of Weekly Exercise Falls Far Short Of Real Heart Protection A Macao Polytechnic University analysis of over 17,000 UK Biobank participants found that the standard 150-minute weekly exercise guideline only reduces cardiovascular risk by 8-9%, while achieving a substantial risk reduction of over 30% requires 560-610 minutes a week, three to four times current recommendations. Only 12% of participants hit that higher threshold. Host Dave Asprey breaks down why public health minimums are a floor, not an optimization target, and what listeners serious about cardiovascular protection should actually be aiming for. Sources: https://medicalxpress.com/news/2026-05-real-heart-weekly-climbs-current.html https://www.medicalnewstoday.com/articles/560-610-minutes-weekly-exercise-lower-cardiovascular-risk-heart-health https://bjsm.bmj.com/content/early/2026/05/19/bjsports-2025-111351 ~~~New Research Clarifies The Mechanism Behind IV Vitamin C's Anti-Cancer Effect Decades after Linus Pauling's high-dose vitamin C claims were dismissed following failed oral-dose trials, researchers have clarified that Pauling had the mechanism right and the delivery method wrong: IV vitamin C bypasses gut absorption limits to reach plasma concentrations up to 100 times higher than oral dosing, generating hydrogen peroxide that is selectively toxic to cancer cells due to their lower catalase levels. A 2024 University of Iowa study found IV vitamin C combined with chemotherapy doubled overall survival in advanced pancreatic cancer patients. Host Dave Asprey reflects on how this vindicates a decades-old idea that was dismissed for the wrong reasons, and what it means for anyone facing a cancer diagnosis. Sources: https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2018.01182/full https://www.cancer.gov/about-cancer/treatment/cam/hp/vitamin-c-pdq https://medicine.uiowa.edu/news/2024/11/high-dose-iv-vitamin-c-plus-chemotherapy-doubles-survival-advanced-pancreatic-cancer This episode is designed for biohackers, longevity enthusiasts, and high-performance listeners who want the latest breakthroughs in neurodegenerative disease, regenerative medicine, metabolic health, and cancer therapeutics, translated into what actually matters for your biology right now. Host Dave Asprey connects clinical trial data, mechanistic research, and decades of context into practical frameworks for taking control of your own health decisions. New episodes every Tuesday, Thursday, Friday, and Sunday. Keywords: PhenoNet PHENOGENE-1A, inhaled cromolyn Alzheimer's, APOE4 genotype Alzheimer's trial, regenerative astrocytes brain repair, University of Zurich brain regeneration, adult neuroplasticity, keratin bone scaffold, sheep's wool regenerative medicine, collagen vs keratin bone repair, aleniglipron oral GLP-1, Structure Therapeutics weight loss drug, oral semaglutide alternative, exercise minutes cardiovascular risk, 150 minutes exercise guideline, Macao Polytechnic University heart study, IV vitamin C cancer, Linus Pauling vitamin C, ascorbate hydrogen peroxide cancer cells, integrative oncology, biohacking news 2026, Thank you to our sponsors! - Visit www.myvitalc.com/davesfav to unlock Dave's discount - Neuronic | Go to www.neuronic.online Code DAVE for $100 off - iRestore | Reverse hair loss at www.irestore.com/DAVE and get exclusive savings on the iRestore Elite, use code DAVE Resources: • Get My 2026 Clean Nicotine Roadmap | Enroll for free at https://daveasprey.com/2026-clean-nicotine-roadmap/ • Get My 2026 Biohacking Trends Report: https://daveasprey.com/2026-biohacking-trends-report/ • Dave Asprey's Latest News | Go to https://daveasprey.com/ to join Inside Track today. • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Join My Substack (Live Access To Podcast Recordings): https://substack.daveasprey.com/ • Upgrade Labs: https://upgradelabs.com Timestamps: 00:00 – Alzheimer's Drug Trial 01:43 – Brain Repair Cells 03:07 – Keratin Bone Scaffolds 04:45 – Oral GLP-1 Pill 05:59 – Minimum Effective Exercise 07:26 – IV Vitamin C Revisited 08:12 – Vitamin C Cancer Trial 09:30 – Takeaway See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Before the hockey mask. Before the machete. Before Jason Voorhees became a horror icon, there was Ari Lehman, the first Jason in 1980's Friday the 13th. Richard explores Jason's unlikely birth, horror as modern mythology, our fascination with evil, the paranormal, and why monsters never really die. GUEST: Ari Lehman holds a singular place in horror history as the first actor to portray Jason Voorhees, delivering the unforgettable final jump scare in the original 1980 Friday the 13th. But Lehman's story extends far beyond Crystal Lake. An accomplished musician, composer, jazz pianist and lifelong student of monster mythology, he has spent decades exploring why horror, fear and supernatural storytelling exert such a powerful hold on us. WEBSITE: https://firstjason.com FOLLOW RICHARD Website: https://www.strangeplanet.ca YouTube: @strangeplanetradio Instagram: @richardsyrettstrangeplanet TikTok: @therealstrangeplanet SUPPORT OUR SPONSORS!!! HIMS Weight Loss By HIMS -HIMS now offers access to an affordable range of FDA-approved GLP-1 medications, including the Wegovy® pill and the Wegovy® pen. Ready to reach your goals? Visit hims.com/strangeplanet to get a personalized, affordable plan that gets you. MARS MEN Mars Men helps you reclaim your edge with natural testosterone support for energy, focus, and strength Go to MenGoToMars.com right now, for a limited time, listeners of this program get 50% off for life, plus free shipping AND 3 free gifts. QUINCE Luxury, European linen that gets softer with every wash! Turn up the luxury when you turn in with Quince. Go to Quince dot com slash RSSP for free shipping on your order and 365-day returns. Now available in Canada, too. CARGURUS CarGurus is the #1 rated car shopping app in Canada on the Apple App and Google Play store. They've got hundreds of thousands of cars from top-rated dealers, plus advanced search tools that let you zero in on exactly what you want. And you can set real-time alerts for price drops and new listings — so you never miss a great deal. Buy your next car today with CarGurus at cargurus dot ca. Go to cargurus dot ca to make sure your big deal is the best deal. ⁠ BECOME A PREMIUM SUBSCRIBER!!!⁠ ⁠https://strangeplanet.supportingcast.fm⁠ Three monthly subscriptions to choose from. Commercial Free Listening, Bonus Episodes and a Subscription to my monthly newsletter, InnerSanctum. Visit ⁠https://strangeplanet.supportingcast.fm⁠ Use the discount code "Planet" to receive $5 OFF any subscription. We and our partners use cookies to personalize your experience, to show you ads based on your interests, and for measurement and analytics purposes. By using our website and services, you agree to our use of cookies as described in our Cookie Policy. Learn more about your ad choices. Visit ⁠megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://strangeplanet.supportingcast.fm/

What did Dr. Anthony Fauci know privately about COVID vaccines—and what was the American public being told at the same time? On this episode of The Truth with Lisa Boothe, Senator Ron Johnson joins Lisa for an explosive conversation about his ongoing investigation into the government's COVID-19 response and newly obtained communications from Fauci’s government-issued devices. Johnson discusses a private Fauci message that he says raised concerns about vaccination and pregnancy, why he believes the issue goes far beyond the debate over miscarriage statistics, and his argument that Americans were denied information necessary to make fully informed medical decisions. The Wisconsin senator also reveals what investigators are finding as they work through tens of thousands of Fauci text messages, hundreds of voice messages and other government records. Johnson explains why identifying the people behind hundreds of phone numbers has become a critical part of the investigation—and why he says his team is being careful not to release private information unrelated to public policy. Lisa and Sen. Johnson also discuss Fauci’s handling of the COVID pandemic, gain-of-function research, vaccine safety surveillance, the relationship between government health agencies and pharmaceutical companies, and Johnson’s allegations that career bureaucrats are resisting efforts to uncover additional records. Johnson says investigators are now seeking devices and communications associated with other former government health officials as his probe expands—and declares that despite years of pursuing answers about the pandemic, the investigation has “only just begun.” Plus, Johnson explains why he believes America still needs a full COVID reckoning before the next public health crisis.See omnystudio.com/listener for privacy information.

CardioNerds (Dr. Apoorva Gangavelli, Dr. Cory Sejo, and Dr. Joseph Kassab), discuss tricuspid regurgitation evaluation and management with Dr. Sunil Mankad. This episode was produced as part of the CardioNerds Academy curriculum by House Einthoven under the guidance of House Chief, Dr. Apoorva Gangavelli and Academy Program Director, Dr. Gurleen Kaur. A matching review article will be published in US Cardiology Review, the official journal of CardioNerds. This discussion was planned in collaboration with the Mayo Clinic Cardiovascular Board Review Course.  Audio editing by CardioNerds intern Emma Winakur. Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. CardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Key Points: Tricuspid regurgitation is common and associated with increased mortality at every stage, regardless of etiology. Outcomes are worse with worsening severity, so accurate grading is critical. Etiology is critical to guide treatment decisions. Etiology includes primary vs secondary (atrial or ventricular) vs CIED-related TR. 3D echocardiography can be very helpful in determining TR etiology, especially in CIED-related TR. Diuresis with the goal of euvolemia is step one. Additionally, underlying contributory conditions (eg. pulmonary HTN, HFrEF, atrial fibrillation) should be addressed, if appropriate, and then TR severity reassessed. The choice between T-TEER and TTVR hinges on anatomy, RV function, pulmonary hypertension, and the ability to tolerate anticoagulation. T-TEER is generally first line in atrial functional TR with appropriate anatomy, in patients with poor RV function who cannot tolerate a sudden increase in RV afterload, or in patients who cannot tolerate the necessary anticoagulation with TTVR. TTVR is preferred with wide coaptation gaps and CIED-related TR. This is a team sport. Multidisciplinary discussions utilizing imaging (TTE/TEE, CT), risk scores (TRI-SCORE or TRIO), patient preference, and prior institutional experience are essential for the effective treatment of severe TR. Notes: What is the clinical importance of tricuspid regurgitation? TR is very common with approximately 4% of people over 75 having moderate or greater severity. TR (even mild) is associated with increased mortality. Those outcomes worsen as the TR severity worsens, and this phenomenon is independent of the mechanism of regurgitation. What is unique about the tricuspid valve compared to the other cardiac valves? It is at an anterior location which allows it to be imaged well with transthoracic echocardiography It is the largest valve and composed generally of 3 leaflets (but very often can have 4+ leaflets). Importantly, the RV is compliant and changes size and shape readily based on loading conditions. The TV annulus similarly changes size and shape based on hemodynamic conditions such as preload. What is a good framework for approaching the causes of tricuspid regurgitation? Determine the presence and define the severity of TR. Using TTE, we want to measure the right atrial size, the RV size, and any other concomitant valvular lesions.  Use TTE (2D and 3D) to characterize leaflet anatomy and characteristics. Subtypes of TR mechanisms (many times etiology is mixed). Primary: primary leaflet abnormality, occurs in ~10% of cases. Look for prolapse, flail, endocarditis, etc. Secondary/functional: leaflets normal but surrounding structures are abnormal. Atrial: RA and tricuspid annular dilation but normal RV size/shape, and can be related to arrhythmias like atrial fibrillation. Ventricular: RV dilated and/or dysfunctional with leaflet tethering. Can be related to pulmonary hypertension or primary RV disease. Cardiac implantable electronic device (CIED): Related to device (usually pacemakers or ICD) interaction with TV leaflets. Includes perforation, entanglement in subvalvular apparatus, impingement, etc. 3D TTE particularly helpful to evaluate How do we grade TR severity? It is very important to grade the severity of TR, and this is generally done with echocardiography. There are both quantitative and qualitative methods which use Doppler and various equations to estimate TR severity. Current recommendations have expanded TR severity beyond mild/moderate/severe to include “massive” and “torrential” categories. The most important parameters measured/calculated are vena contracta width, regurgitant volume, regurgitant fraction, and effective regurgitant orifice area. Helpful qualitative metrics include hepatic venous flow reversal. When should additional studies beyond transthoracic echocardiography, such as transesophageal echocardiography (TEE), cardiac computed tomography (CT), and cardiac magnetic resonance imaging (MRI) be pursued? TEE is particularly helpful if TTE views are poor. Since TEE is used during transcatheter intervention, a pre-procedure TEE to define anatomy, determine procedure candidacy, and plan for the procedure is critical.  CT is also helpful for procedure planning and has particular strengths in defining annulus size and geometry. A CT is required prior to transcatheter tricuspid valve replacement (TTVR). MRI is helpful for measuring RV volumes and function, but is not generally used to assess TR severity.  What is the approach to the treatment for severe tricuspid regurgitation? The first step is to try to determine the etiology. For secondary TR, treating the underlying condition is indicated. For example, pulmonary vasodilators for pulmonary HTN or guideline therapy for heart failure with reduced ejection fraction. Diuretics are the mainstay for treatment, with the goal to obtain euvolemia. This may require inpatient admission to optimize volume status and medication regimen. Once reversible etiologies are addressed, if the patient is still symptomatic from TR, additional therapies can be considered. What is the role of right heart catheterizations (RHC) in patients with severe TR? RHC is very helpful for many reasons. We use it in TR to help determine volume status, cardiac output, and RV function. Additionally, identifying and characterizing pulmonary hypertension (with pulmonary artery pressures and calculating pulmonary vascular resistance) is an important factor when choosing future therapies.  With severe tricuspid regurgitation, when should we refer for intervention (either with surgery or transcatheter repair or replacement)? Once reversible etiologies are addressed and euvolemia has been achieved, if the patient is still symptomatic from TR despite aggressive medical optimization, additional therapies can be considered. Once euvolemic, a repeat TTE should be ordered to reassess the severity of the TR. Use calculators (for example, either the TRI-SCORE or TRIO score) to predict operative mortality for isolated TR surgery. What are our transcatheter treatment options in severe tricuspid regurgitation, and how do we choose between them? The primary approved transcatheter treatment options for severe TR include transcatheter tricuspid edge-to-edge repair (T-TEER) and transcatheter tricuspid valve replacement (TTVR), of which the Edwards EVOQUE valve is the only one currently approved by the FDA. There are other TTVR device under investigation. These decisions should be made with a multi-disciplinary team including representation from cardiac imaging, interventional cardiology, and cardiothoracic surgery. Factors that go into the decision between T-TEER and TTVR include anatomy (annulus width, coaptation gap, leaflet length), RV reserve, pulmonary hypertension presence, ability to tolerate anticoagulation, patient preference, and institutional experience.  T-TEER is generally the first line with atrial functional and suitable anatomy. It is successful at reducing TR but does not generally eliminate it.  TTVR with EVOQUE is preferred in certain anatomic considerations like a large coaptation gap or when there is CIED-related TR (as this was excluded in T-TEER trials). Patients must be suitable for anticoagulation to receive TTVR as there is risk of leaflet thrombosis without it. If moderate/severe pulmonary hypertension is present, or there is poor RV function, TTVR may be avoided as the sudden elimination of TR causes a sudden increase in RV afterload which may not be tolerated. What is the role in advanced metrics for evaluating RV function? Advanced metrics like RV/PA coupling are under investigation but have not made it into the guidelines. The clinical utility is not yet known.  Assessing the RV function is important as stated above. Dr. Mankad prefers using 3D TTE to calculate an RVEF, or tracking RV longitudinal free wall strain. If you do encounter CIED-related TR, how do you treat it? Evaluate with TTE or TEE. 3D is very helpful to identify relative anatomy and leaflet-device interactions. There is no clear consensus about treatment if CIED-related TR is the primary mechanism of severe TR. If recently implanted, repositioning may be a valid option, but requires discussions with multiple teams including electrophysiology, advanced cardiac imaging, CT surgery, and interventional cardiology. References O’Gara PT, Lindenfeld J, Hahn RT, et al. 10 Issues for the Clinician in Tricuspid Regurgitation Evaluation and Management: 2025 ACC Expert Consensus Decision Pathway. J Am Coll Cardiol. 2025;S0735-1097(25)07047-0. O’Gara PT, Little SH, Badhwar V, et al. Operator and Institutional Recommendations and Requirements for Tricuspid Interventions: 2026 ACC/AHA/ASE/HRS/STS Expert Consensus Systems of Care Document. J Am Coll Cardiol. 2026;S0735-1097(26)05481-1. Hahn RT. Tricuspid Regurgitation. N Engl J Med. 2023;388(20):1876-1891. Davidson LJ, Tang GHL, Ho EC, et al. The Tricuspid Valve: A Review of Pathology, Imaging, and Current Treatment Options: A Scientific Statement From the American Heart Association. Circulation. 2024;149(22):e1223-e1238.

Guest: Jerold MandeShow Notes:What if improving health means not just having enough food—but having access to the right kinds of food? This episode explores how nutrition security, public policy, and healthcare systems work together to shape diet quality and chronic disease prevention—and what it will take to build a healthier future.Guest Bio:Jerold Mande is CEO of Nourish Science; Adjunct Professor of Nutrition, Harvard T.H. Chan School of Public Health; and a Non-Resident Senior Fellow, Tisch College of Civic Life, Tufts University. For most of his career, he has served in senior federal food, nutrition, and health policy positions, including the FDA and USDA. Quote:"Food security just means people have access to food, but it doesn't mean they have access to food that they'll thrive on."Question of the Day:What changes, whether in policy or your local community—would make it easier for people to access nutritious food where you live?On This Episode You Will Learn:The difference between food security and nutrition security, and why both matter for preventing chronic disease.How government policies and food programs influence the foods we see in grocery stores, schools, and communities.Why ultra-processed foods have become such a big part of the American diet and how they may affect our health.The story behind the Nutrition Facts label and MyPlate, and how they changed the way Americans think about nutrition.What changes in food policy and nutrition research could help create a healthier future for everyone.Connect with Yumlish!Yumlish Website: YumlishYumlish on Instagram: @yumlish_Yumlish on Facebook: YumlishYumlish on Twitter: @yumlish_Yumlish on LinkedIn: YumlishConnect with Jerold Mande!Website URL: https://nourishscience.org/ https://hsph.harvard.edu/profile/jerold-r-mande/Twitter(X) URL: @JerryMandeLinkedIn URL: www.linkedin.com/in/jerold-mande

Most companies bring in regulatory expertise when they're ready to file. Leland Keyt, VP of Regulatory Affairs and Quality Assurance at Apreo Health, makes the case that by then you've already absorbed costs you didn't need to, and explains what early regulatory partnership actually looks like in practice.Leland and Nick get into why risk tolerance is the thing that catches scaling companies, the hidden costs of rework beyond timeline, how regulatory input changes product decisions across geographies, and what regulators are scrutinizing more closely now.A few of Leland's key takeaways:Early means concept phase, not pre-submission. Even your IP narrative can matter years later in a submissionCompanies often run more testing than they need. Efficiency means answering the right questions with the least dataRisk tolerance is what gets companies in trouble. What's acceptable in development isn't acceptable at PMAPost-market obligations happen underneath the water, and they're a resourcing problem more than a regulatory oneRework isn't just timeline, it's product cost and a supply chain issueBiocompatibility interpretation varies by geography and can change what you develop and whenAI, usability, and management review are all getting closer regulatory attentionBuild a scalable QMS. It's the bedrock, and it isn't an afterthoughtAbout Leland KeytLeland Keyt is VP of Regulatory Affairs and Quality Assurance at Apreo Health, which is running a US pivotal study for an implantable airway scaffold for severe emphysema. She has over 20 years in medical devices across startups, mid-size companies, and multinationals, previously serving as Chief Product Officer at Biorithm and Senior Director of RA/QA at Pulmonx, where she navigated FDA's Breakthrough Device Program to a 178-day PMA approval.About The FDA GroupThe FDA Group helps life science organizations rapidly access the industry's best consultants, contractors, and candidates. Our resources assist in every stage of the product lifecycle, from clinical development to commercialization, with a focus on staff augmentation, auditing, remediation, QMS, and other specialized project work in Quality Assurance, Regulatory Affairs, and Clinical Operations. Learn more: https://www.thefdagroup.com/

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of compelling stories that underscore the dynamic shifts and groundbreaking progress within the industry. Recently, Akeso's ivonescimab received a landmark approval for first-line treatment of non-small cell lung cancer (NSCLC) in China. This marks a significant shift in China's regulatory environment, which is increasingly fostering innovative treatment options. Ivonescimab's approval not only enhances Akeso's standing in oncology but also provides new hope for NSCLC patients, a cancer type notoriously difficult to treat. In the arena of mergers and acquisitions, Alfasigma has strategically expanded its reach by acquiring key assets from Nordic Pharma. This acquisition opens doors to new therapeutic areas like arthritis, women's health, and critical care—an astute move to diversify offerings and enhance global market presence. Such strategic expansions are essential for companies aiming to maintain competitive edge and explore untapped markets. Eli Lilly has taken legal action against six U.S. companies involved in unauthorized sales of its experimental weight-loss drug, retatrutide. This highlights ongoing challenges in intellectual property protection, emphasizing the balance between innovation safeguarding and market expansion. The legal actions are part of broader efforts to preserve public safety and ensure proper distribution channels for groundbreaking therapies. On the quality control front, Fresenius faced a setback with the recall of a batch of Actemra biosimilars due to glass particle contamination concerns. This incident serves as a stark reminder of the critical role rigorous quality assurance plays in pharmaceutical manufacturing, especially as biosimilars gain traction for their cost-effectiveness and accessibility. In an intriguing blend of technology and healthcare, Samsung Electronics has secured FDA clearance for its Galaxy Buds earphones to function as over-the-counter hearing aids. This development illustrates the increasing convergence of consumer electronics with medical devices, offering innovative solutions to enhance accessibility in hearing health. Turning to psychedelic therapies, Definium Therapeutics reported significant success in its Phase 3 trials for an LSD-based formulation targeting generalized anxiety disorder. Building on earlier successes in depression studies, Definium is paving the way for psychedelic compounds in mainstream medicine. The results not only bolster confidence in such therapies but also signal a potential paradigm shift in treating mental health disorders. Moreover, Oracle Health has introduced an upgraded patient portal featuring an AI assistant designed to simplify medical records management and appointment scheduling. This advancement is part of a larger trend towards integrating artificial intelligence into healthcare systems to improve patient engagement and streamline processes, ultimately enhancing healthcare delivery efficiency. BridgeBio's ATTR stabilizer Attruby achieved impressive quarterly sales of $222 million, nearing blockbuster status as it captures significant market share in treating transthyretin amyloidosis (ATTR). This success underscores the growing importance of small molecule therapies in addressing complex cardiovascular conditions and reflects an industry trend towards stabilizer-first markets. InduPro has successfully raised $77 million in Series B funding supported by industry leaders like Sanofi and Lilly. The investment is set to propel their cancer pipeline forward with a focus on induced proximity and bispecific antibody platforms—innovations poised to revolutionize oncology treatment by enhancing drug specificity and efficacy. On the regulatory front, Chiesi UK's delayed-release mercaptamine received NHS endorsement for cystinosis treatment—an advancement that expands therapeutic options for patients requiring cystine-depleting therapy. Such regulatory support is crucial for facilitating access to innovative treatments for rare diseases. Amidst these developments, Gilead Sciences licensed MacroGenics' bispecific antibody program—a strategic move to bolster its oncology portfolio through milestone payments and royalties. This reflects a broader industry pattern where larger pharmaceutical companies seek pipeline diversification through strategic partnerships and acquisitions of innovative technologies. In vaccine development news, StablePharma's SPVX02 tetanus-diphtheria vaccine achieved promising Phase 1 results without refrigeration requirements—an innovation that could significantly enhance global vaccination efforts by overcoming cold chain distribution challenges. Finally, Insilico Medicine stands at the forefront of AI integration into drug discovery processes under CEO Alex Zhavoronkov's leadership. By promoting a 'fail-fast' approach at the Bio International Convention, Insilico aims to accelerate drug development timelines while reducing costs—a strategy indicative of biopharma's evolution towards more data-driven decision-making processes. These stories collectively highlight an era marked by rapid innovation within pharmaceuticals and biotech sectors. As companies navigate these complexities through scientific advancements and strategic maneuvers alike—there lies immense potential not only for enhancing patient care but also driving economic growth across global healthcare landscapes.Support the show

Episode 2014  Brought to you by our incredible sponsor: Mars Men - For a limited time, our listeners get 50% off FOR LIFE, Free Shipping, AND 3 Free Gifts at Mars Men at Mengotomars.com 00:00:00 Timestamps 00:03:00 The Patriot Games are taking place on ESPN+ and are not great 00:10:45 New alarming trend with dudes publicly gooning at chicks at Dollar Tree stores  00:22:30 FDA recalls blood pressure meds, Argentine beef recalled and Taylor Farms guac  00:26:40 Someone has seen a live playthrough of Elder Scrolls VI 00:30:20 Finnish man builds 20k solar yacht that requires no fuel and goes forever  00:32:30 A lab in China has invented night vision contact lenses For more head over to patreon.com/hardfactor for weekly bonus episodes and most importantly HAGFD! Learn more about your ad choices. Visit megaphone.fm/adchoices

Legal team, on the docket this week we have two more medical malpractice cases against the self-described ‘Boob God' and ex-husband of RHOM star Lisa Hochstein: Lenny Hochstein. A warning to all that one of these cases involves some graphic details of a ‘mommy makeover' gone wrong. We're tying up the Pauline Pearlman case from last week, breaking down Alan Jaffery and Miriam Pavlovsky's claims of poor pre and post-operative management, and discussing what Lenny's defenses might be in both cases.What's on the docket?Angela's car accident and PSA to always wear your seatbelt!!Tying up Pauline Pearlman caseConsumer Review Fairness ActLenny suing RealSelf and patients who posted bad reviewsCesie watching Madmen for the first timeAlana Jaffery v. Lenny HochsteinBreaking down Alan Jaffery's claims including surgery risks and post-operative managementAmerican Society of Plastic Surgeons Mommy Makeover handbookHow important it is to stay where you get your surgery done for enough time to healCesie and Angela's Oura ringsWhat probate court is for typically vs. in TexasThe medical theories around what may have happened in Alana's surgeryFlorida's cap for medical malpractice casesBotched and Cesie's Paul Nassif spotting in LAWhat Lenny's defenses might beMiriam Pavlovsky v. Lenny HochsteinWhat wasn't disclosed to Miriam pre-surgeryCesie's love of the show ChoppedSet of risks with different types of surgeryWhat does pre-market approval for a medical device mean (FDA approved vs. FDA cleared)Criteria for suing a doctor for medical malpractice in FloridaMiriam's corrective surgery, additional complications, and what she continues to suffer fromUpdate on Lisa HochsteinAccess additional content and our Patreon here: ⁠https://zez.am/thebravodocket⁠ The Bravo Docket podcast, the statements we make whether in our own media or elsewhere, and any content we post are for entertainment purposes only and do not provide legal advice. Any party consuming our information should consult a lawyer for legal advice. The podcast, our opinions, and our posts, are our own and are not associated with our employers, Bravo TV, or any other television network. Cesie is admitted to the State Bars of California and New York. Angela is admitted to the State Bars of Texas, Kansas, and Missouri. Thank you to our incredible sponsors!Hers: Ready to reach your goals? Visit forhers.com/bravodocket to get personalized, affordable care that gets you.Fabletics: Shop now at Fabletics.com/docket to get 70-80% off everything when you sign up as a new VIP. Wayfair: Join Wayfair Rewards today to get 5% back on every purchase and start saving on your next home upgrade. Head to Wayfair.com right now to shop all things home and get your space ready for less.Boll and Branch: Get 15% off your first order plus free shipping at BollAndBranch.com/docket with code docket.Warby Parker: Right now, buy one pair of glasses and get 20% off any additional pairs at WarbyParker.com/DOCKET.Whatnot: Download the Whatnot app today and get $20 off and free shipping on your first purchase.Honeylove: Save 20% Off Honeylove by going to honeylove.com/DOCKET #honeylovepodQuince: Upgrade your everyday. Download the Quince app for app-exclusive offers, or go to Quince.com/DOCKET for free shipping on your order and 365-day returns. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Andrea breaks down the latest FDA news surrounding BPC-157 and explains what the recent recommendation really means without the hype. She shares why this peptide has been on her radar for years, her own personal experience using it for recovery, what current research is exploring, and why it's become such a popular topic in the fitness and wellness world. Whether you've heard people talking about BPC-157 or you're simply curious about the buzz, this episode offers a balanced, easy-to-understand overview of where things stand today.Make Fit Simple is sponsored by KION Go to Getkion.com/simple for 20% off.Join my newsletter!  https://www.deliciouslyfitnhealthy.com/emlsFollow the Make Fit Simple Podcast@MakeFitSimplePodcastHave a suggestion for a topic click HEREHave a suggestion for a guest click HERENEW! Leave a question for Andrea HERE on SpeakPipe!Follow Andrea on Instagram@deliciouslyfitnhealthy@dfh.training.picsTraining & Coachinghttps://www.deliciouslyfitnhealthy.com/linksVisit Andrea's Websitewww.deliciouslyfitnhealthy.comProduced by Light On Creative Productions 

UFOs have escaped the fringe. With TIME declaring “The New Case for Aliens,” filmmaker and MUFON Media Relations Director Ron James joins Richard Syrett to examine the state of Disclosure, emerging government files, scientific acceptance, and the bigger question: Are we witnessing genuine transparency—or a carefully managed narrative? GUEST: Ron James is an award-winning filmmaker, investigative researcher, and Media Relations Director for the Mutual UFO Network (MUFON). He is the creator of the acclaimed Accidental Truth documentary series, exploring the evidence surrounding UAPs and the political, scientific, intelligence, and cultural forces shaping the Disclosure debate. His work asks a question increasingly central to the UFO mystery: Who controls what the public is allowed to know? WEBSITES: https://www.facebook.com/RonJamesTelevision https://www.accidentaltruthnext.com/ FILMS: Accidental Truth Accidental Truth: Next FOLLOW RICHARD Website: https://www.strangeplanet.ca YouTube: @strangeplanetradio Instagram: @richardsyrettstrangeplanet TikTok: @therealstrangeplanet SUPPORT OUR SPONSORS!!! HIMS Weight Loss By HIMS -HIMS now offers access to an affordable range of FDA-approved GLP-1 medications, including the Wegovy® pill and the Wegovy® pen. Ready to reach your goals? Visit hims.com/strangeplanet to get a personalized, affordable plan that gets you. MARS MEN Mars Men helps you reclaim your edge with natural testosterone support for energy, focus, and strength Go to MenGoToMars.com right now, for a limited time, listeners of this program get 50% off for life, plus free shipping AND 3 free gifts. QUINCE Luxury, European linen that gets softer with every wash! Turn up the luxury when you turn in with Quince. Go to Quince dot com slash RSSP for free shipping on your order and 365-day returns. Now available in Canada, too. CARGURUS CarGurus is the #1 rated car shopping app in Canada on the Apple App and Google Play store. They've got hundreds of thousands of cars from top-rated dealers, plus advanced search tools that let you zero in on exactly what you want. And you can set real-time alerts for price drops and new listings — so you never miss a great deal. Buy your next car today with CarGurus at cargurus dot ca. Go to cargurus dot ca to make sure your big deal is the best deal. ⁠ BECOME A PREMIUM SUBSCRIBER!!!⁠ ⁠https://strangeplanet.supportingcast.fm⁠ Three monthly subscriptions to choose from. Commercial Free Listening, Bonus Episodes and a Subscription to my monthly newsletter, InnerSanctum. Visit ⁠https://strangeplanet.supportingcast.fm⁠ Use the discount code "Planet" to receive $5 OFF any subscription. We and our partners use cookies to personalize your experience, to show you ads based on your interests, and for measurement and analytics purposes. By using our website and services, you agree to our use of cookies as described in our Cookie Policy. Learn more about your ad choices. Visit ⁠megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://strangeplanet.supportingcast.fm/

President Trump signed an executive order updating recommended childhood immunizations—reducing the core schedule from 18 vaccines down to protections against 11 diseases, spacing out doses, and recommending single-dose MMR options. While medical and scientific consensus maintains there is no link between vaccines and autism, both the President and Health and Human Services Secretary Robert F. Kennedy Jr. suggested at the signing that a link may exist between the expanded schedule and rising autism rates. Dr. Stephanie Haridopolos from the Department of Health and Human Services (HHS) joins the Rundown to examine what this new guidance actually changes. She discusses HHS's approach to vaccine safety research, efforts to rebuild public trust, pediatric recommendations, and the administration's plan to investigate potential environmental triggers behind brain inflammation and autism.The restaurant industry is navigating complex challenges in food safety as recent FDA investigations into widespread foodborne outbreaks leave consumers on edge. Chef and restaurateur David Burke joins to discuss how his 18 locations manage major supply recalls through centralized buying, the pros and cons of local sourcing versus large distributors, and practical advice for consumers navigating food safety concerns when dining out. PLUS, commentary by Jason Chaffetz, FOX News contributor and the host of the Jason In The House podcast on FOX News Radio.  Learn more about your ad choices. Visit podcastchoices.com/adchoices

Urge urinary incontinence (UUI) places a significant emotional and physical burden on women affected. Sacral neuromodulation has been and remains a well-established implant-based therapy for UUI. The concept originated in the early 1970s from sacral anterior root stimulation research for neurogenic bladder, with human clinical trials beginning in 1982. Medtronic's InterStim device received FDA approval in 1997 for UUI, and in 1999 for urgency-frequency and nonobstructive urinary retention. This was a game changer for affected women. Now, as of August 5, 2026, the FDA has granted 510(k) clearance for a new, less invasive neuromodulation implant- placed in the ANKLE. This is the Revi Extend Implant system (BlueWind Medical). What was the phase 3 data on this? What does the “wearable controller device” look like? Listen in for details. 1. Lukacz ES, Santiago-Lastra Y, Albo ME, Brubaker L. Urinary Incontinence in Women: A Review. JAMA. 2017;318(16):1592–1604. doi:10.1001/jama.2017.121372. Amundsen CL, Sutherland SE, Heesakkers JPFA, et al. Three-year efficacy and safety of Revi implantable tibial neuromodulation from the pivotal OASIS study. J Urol. 2026;216(2):219-229. doi:10.1097/JU.00000000000050623. BlueWind Medical receives FDA 510(k) clearance for Revi Extend implant. News release. BlueWind Medical Ltd. August 5, 2026. Accessed August 5, 2026. https://www.businesswire.com/news/home/20260805290667/en/BlueWind-Medical-Receives-FDA-510k-Clearance-for-Revi-Extend-Implant

On this episode of Vitality Radio, Jared continues his Topical Medicine Cabinet series with the products he reaches for most to apply topically for healthy skin, skin comfort, and everyday first aid. He explains why nano silver gel has become his go-to for everything from post-shaving care and natural deodorant to supporting the skin's natural healing process after minor burns and blemishes. He also explores the benefits of whipped beef tallow, herbal balms featuring traditionally used botanicals like comfrey and calendula, natural options for itchy skin, and topical essential oil blends for occasional tension headaches. Along the way, Jared breaks down the science, traditional herbal wisdom, and practical ways to build a natural topical medicine cabinet for the whole family.Products:Vitality Nutrition Nano-Silver Skin GelAtrubein Whipped Dream Beef Tallow Body CreamRoots & Leaves Whipped Tallow BalmGolden Age Naturals Tallow BalmAuminay Itch-Away BalmAuminay Herbal BalmQuantum Lysine OintmentQuantum Lysine Lip BalmAuminay Tension TamerAdditional Information:663: Topical Medicine Cabinet - Part 1: Pain, Injury & Muscle Recovery  Visit the podcast website here: VitalityRadio.comYou can follow @vitalitynutritionbountiful and @vitalityradio on Instagram, or Vitality Radio and Vitality Nutrition on Facebook. Join us also in the Vitality Radio Podcast Listener Community on Facebook. Shop the products that Jared mentions at vitalitynutrition.com. Let us know your thoughts about this episode using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Thank you!Just a reminder that this podcast is for educational purposes only. The FDA has not evaluated the podcast. The information is not intended to diagnose, treat, cure, or prevent any disease. The advice given is not intended to replace the advice of your medical professional.This podcast is produced by DrTalks.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drtalks.com/podcast-service/⁠

Send us Fan MailProbiotics left US NICUs after the FDA reclassified them, and NEC rates went up. This week Ben reviews the Connection Study, a 2,158 infant phase 3 trial of IBP-9414, a live biotherapeutic product containing Limosilactobacillus reuteri, run under an IND with the regulatory rigor probiotics never had. Neither primary endpoint reached significance, but all cause mortality fell 27%, and surgically confirmed NEC favored treatment after 14 days of dosing. The discussion may be the real story, including a kappa of 0.36 between radiologists reading the same NEC films. Ben and Daphna talk through what a regulated probiotic would mean for the babies waiting now.----Live biotherapeutic product IBP-9414 (L. reuteri) in very low birth weight infants: the Connection Study. Neu J, Del Moral T, Guthrie SO, Hudak ML, Indrio F, Kim JH, Kronström A, Martin CR, Modi N, Rastad J, Schnitzer TJ, Singh R, Strömberg S, Szajewska H, Thuresson M, Caplan M.Pediatr Res. 2026 Feb 20. doi: 10.1038/s41390-026-04826-7. Online ahead of print.PMID: 41721054Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

A blistering, high-energy breakdown uncovering newly highlighted disclosures, private text chains, and leaked audio surrounding COVID-19 vaccine policy and censorship! The discussion dives deep into the upcoming FDA-approved mRNA flu vaccine, exposing critical safety data hidden behind study paywalls and warning listeners about potential risks. Plus, updates on immigration deportation records, Florida's potential legal actions, and the ongoing fight for medical transparency!

What happens when someone who volunteered for a COVID-19 vaccine clinical trial says the shot changed her life within hours? On this episode of The Tudor Dixon Podcast, Tudor sits down with Brianne Dressen, co-founder of React19 and a participant in the AstraZeneca COVID-19 vaccine clinical trial, to discuss her experience with what she describes as a severe and lasting vaccine injury. Dressen recounts developing neurological symptoms shortly after receiving the shot, including burning and tingling, numbness, difficulty walking, sensitivity to light and sound, vision problems, and cognitive issues. She says some symptoms remain with her nearly six years later. She also describes receiving treatment at the National Institutes of Health, saying the intervention produced a significant improvement but that she has continued to require treatment. Tudor and Dressen discuss informed consent during vaccine trials, the treatment of people reporting adverse events, Anthony Fauci and the NIH, pharmaceutical-company accountability, and Dressen's allegations that officials knew more about certain adverse effects than was publicly acknowledged. Dressen also explains why she believes further federal investigation is necessary. It’s a wide-ranging conversation about one woman's experience, unanswered questions from the COVID era, and the continuing debate over transparency, medical treatment, and accountability. Subscribe to The Tudor Dixon Podcast on iHeartRadio, Apple Podcasts, YouTube, and wherever you get your podcasts.See omnystudio.com/listener for privacy information.

Are PPOs quietly costing your dental practice hundreds of thousands of dollars? In this episode, PPO expert Shelley DeGroff reveals how hidden contract terms, outdated reimbursement rates, and insurance strategies can significantly reduce profitability without most dentists even realizing it.Host Art Wiederman sits down with Shelley DeGroff, founder of PPO Advisors, to unpack the complex world of PPO insurance and explain why understanding your contracts is one of the fastest ways to improve your practice's financial health. Shelley shares how insurance companies use data mining to monitor practices, why dentists should regularly negotiate reimbursement rates, and how many providers unknowingly accept lower payments because they are contracted through multiple hidden network agreements.The conversation also explores common mistakes that can expose practices to compliance risks, including improper patient discounts and NPI credentialing fraud during practice transitions. Shelley explains why these issues are more serious than many dentists realize and offers practical guidance for avoiding costly mistakes. The episode concludes with advice on evaluating whether to stay in network or transition out of network, emphasizing that the right strategy depends on your practice goals, patient relationships, and long term profitability. Dentists will leave with a better understanding of how to take control of their insurance participation instead of letting insurance companies dictate the future of their practice.Connect with Shelley!

News: After Aid Cuts, US Announces $2 Billion for Christian Groups @1:22 Greenland issues ‘strong warning' as Trump-linked oil firm prepares to drill @2:48 Politics: Religious Liberty Commission lawsuit dismissed @5:38 Dan Patrick directs Texas Senate to study ways to further religion @8:54 Lt. Gov. Beckwith wants Indiana candidates to attest belief @10:17 Trump hid in catering truck in secret plane swap over Iran threat @12:21 Max Miller tangent @17:55 Trump-backed candidate Amir Hasaan in Michigan loses @19:25 Health/Medicine/Science: Trump signs executive order on childhood vaccine recommendations @23:50 Report: Trump mad RFK Jr. hasn't cut more vaccines or proven autism link @25:06 Stop 'Harassment' of Fauci, Scientists Urge Politicians @26:39 Dr. Anthony Fauci repeatedly invokes the Fifth in Senate hearing Ripple Effect Why? Anecdote Dinosaur soft tissue @32:16 Circumcision and Autism: What a New Study Found @37:35 The Peptide Wild West @40:24 Maharashtra allows homeopaths to prescribe allopathic medicines @44:12 Good news Moderna's mRNA flu shot earns FDA approval after rollercoaster review @46:20 Austin ISD vaccination rates surpass 95% after sharp rebound @47:11 Religious Nonsense: Young Latinos abandoning churches to be "nones" @48:01 Final Stories: Posts claim Earth will 'lose gravity' for 7 seconds on Aug. 12, 2026 @49:03

The National Drug Code (NDC) is a critical identifier used throughout the healthcare supply chain, supporting product identification across manufacturers, distributors, pharmacies, providers, payers, and data systems. In this episode, Reid Jackson and Liz Sertl chat with Ullrich Mayeski, Community Engagement Director - Healthcare at GS1 US. He explains the FDA's transition from the current 10-digit NDC format to a 12-digit format planned for 2033. Ullrich discusses why the change is happening, how the update will affect healthcare organizations, and why businesses should begin reviewing the systems, processes, and trading partner connections that rely on NDC data. The conversation explores the move toward a consistent NDC structure, the role of 2D barcodes, and how better product identification can support traceability, data exchange, and patient safety throughout the healthcare supply chain. In this episode, you'll learn: Why the NDC transition from 10 digits to 12 digits is reshaping healthcare product identification The biggest challenges manufacturers, distributors, pharmacies, and providers face as they prepare for the 2033 change How standardized data and 2D barcodes can improve product information, traceability, and supply chain communication    Things to listen for: (00:00) Introducing Next Level Supply Chain (02:11) Ullrich's role supporting healthcare organizations at GS1 US (03:54) Why the National Drug Code is a critical healthcare identifier (06:24) Why the NDC format is changing from 10 digits to 12 digits (08:23) How the new format supports greater consistency across systems (10:49) Why the transition affects more than pharmaceutical manufacturers (13:32) The systems and processes organizations need to evaluate (17:27) How over-the-counter products are also affected (19:19) Why organizations should begin preparing now (23:36) How the NDC transition connects to traceability and 2D barcode adoption (26:21) How better data capture can support patient safety   Connect with GS1 US: Our website - www.gs1us.orgGS1 US on LinkedIn Connect with the guest: Ullrich Mayeski on LinkedIn  

Send us Fan MailStella Fosse was a teenager when she determined to publish her first book by the age of 25. That didn't happen.  She published her first book at 68. And it was very different from her early aspirations.Join host Jane Trombley in conversation with Stella, a former Biotech writer who pivoted to “elderotica” — in both nonfiction and as a thread throughout her novels.  During a 25-year career as a tech writer, Stella focused on writing, submitting applications, and gaining FDA approval for Biotech products. Along the way, she joined a group of women authors reading their erotic essays featuring powerful female central characters. Stella began to dabble in the genre, participating in writing and reading her work, what she called “elderotica.” It was time to pivot.  With little more than an idea for a guide for midlife women exploring erotica, Stella published her first book, Aphrodite's Pen: The Power of Writing Erotica After Midlife. It would come as no surprise that the launch party for Aphrodite's Pen was held at a sex toy shop in Berkeley, CA. The rest, as they say, is publishing history. Stella shows us the power of the pivot and a commitment to advocating for women's creativity, often emerging in midlife and beyond. Come join the conversation.Show Notes:Website:  www.stellafosse.comSubstack: stellafosse.substack.comGrandmother Collective on SubstackCrone HubStella's BooksRock On: Power, Sex and Money after 60Write & Sell a Well-Seasoned Romance:Launch Your Author Adventure in Late-Life RomanceVampires of a Certain Age:Five Hundred Years of LovingBrilliant Charming Bastard:Getting Rich is the Best RevengeThe Erotic Pandemic Ball:  Tales of Love in LockdownAphrodite's Pen: The Power of Writing Erotica After MidlifeMentioned in the episode:Joan PriceRuth SaxtonSibylline PressSupport the show

President Trump signed an executive order updating recommended childhood immunizations—reducing the core schedule from 18 vaccines down to protections against 11 diseases, spacing out doses, and recommending single-dose MMR options. While medical and scientific consensus maintains there is no link between vaccines and autism, both the President and Health and Human Services Secretary Robert F. Kennedy Jr. suggested at the signing that a link may exist between the expanded schedule and rising autism rates. Dr. Stephanie Haridopolos from the Department of Health and Human Services (HHS) joins the Rundown to examine what this new guidance actually changes. She discusses HHS's approach to vaccine safety research, efforts to rebuild public trust, pediatric recommendations, and the administration's plan to investigate potential environmental triggers behind brain inflammation and autism.The restaurant industry is navigating complex challenges in food safety as recent FDA investigations into widespread foodborne outbreaks leave consumers on edge. Chef and restaurateur David Burke joins to discuss how his 18 locations manage major supply recalls through centralized buying, the pros and cons of local sourcing versus large distributors, and practical advice for consumers navigating food safety concerns when dining out. PLUS, commentary by Jason Chaffetz, FOX News contributor and the host of the Jason In The House podcast on FOX News Radio.  Learn more about your ad choices. Visit podcastchoices.com/adchoices

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the dynamic landscape of drug manufacturing, regulatory affairs, and scientific breakthroughs that are shaping the future of patient care and therapeutic innovation. Bristol Myers Squibb has made headlines with its substantial $2.3 billion investment in a new manufacturing campus in Houston. This strategic move aims to significantly bolster their capabilities across various modalities including small molecules, biologics, and antibody-drug conjugates. The establishment of this facility is a testament to the growing demand for advanced manufacturing infrastructure needed to support complex therapeutics production. As BMS strengthens its operational capacity, it positions itself to better meet the increasing global demand for innovative treatments. In parallel developments, Jazz Pharmaceuticals is expanding its rare epilepsy pipeline through a $1.3 billion acquisition of Actio Biosciences. This strategic acquisition aligns with Jazz's focus on rare diseases with significant unmet medical needs. By integrating Actio's novel small molecule approach, Jazz aims to leverage these innovative therapies to improve patient outcomes in the rare epilepsy market, highlighting a critical shift towards targeted treatments. Vaderis Therapeutics has successfully raised $152 million in Series B funding, aimed at advancing its AKT-targeting treatment for hereditary hemorrhagic telangiectasia (HHT). This funding will support clinical development efforts, offering hope for patients with this rare vascular disorder who currently have limited therapeutic options. The advancement of such targeted therapies underscores the growing focus on addressing rare diseases within the biotech sector. Clinical trial advancements remain pivotal, with MoonLake Immunotherapeutics reporting positive Phase 3 data for sonelokimab, an IL-17A/F inhibitor targeting psoriatic arthritis. This nanobody-based antibody offers a novel mechanism of action by modulating autoimmune pathways involved in psoriatic arthritis, demonstrating the potential of biologics in managing complex autoimmune conditions. In a transformative approach to drug discovery, Aureka Biotechnologies has raised $100 million in Series B funding to further its platform-enabled efforts in antibody and protein design using AI and machine learning technologies. This integration represents a significant step forward, enhancing efficiency and precision in identifying viable therapeutic candidates. Despite these advancements, regulatory challenges persist. The FDA recently rejected ITM Isotope Technologies' application for 177Lu-edotreotide due to manufacturing concerns related to gastroenteropancreatic neuroendocrine tumors. Such setbacks underscore the critical importance of robust manufacturing practices and regulatory compliance to ensure patient safety and product efficacy. BridgeBio and Alnylam Pharmaceuticals are engaged in a competitive race targeting first-line ATTR-CM patients with differing therapeutic approaches—“silencer” versus “stabilizer” therapies. This debate highlights the intricacies involved in treating transthyretin amyloidosis (ATTR), a condition affecting the heart and nervous system, pointing towards potential breakthrough treatments that could significantly improve patient outcomes. On the regulatory front, President Donald Trump has signed an executive order aimed at revising pediatric vaccine recommendations, reflecting a shift in public health policy that could affect vaccination rates and parental decision-making regarding childhood immunizations. WuXi AppTec recently secured a temporary victory in its legal battle with the U.S. Department of Defense regarding its classification as a Chinese military company. This case highlights the geopolitical complexities faced by global pharmaceutical companies operating in sensitive markets. Meanwhile, technological innovation continues to shape healthcare delivery, exemplified by Abbott's partnership with Google Health to develop an AI-powered health insights application. This collaboration is part of a growing trend toward integrating digital technologies into healthcare to enhance diagnostics and personalized medicine. Finally, strategic corporate restructuring is evident as Aura Biosciences refocuses its R&D efforts on ocular oncology under new leadership. Such moves reflect broader trends within biotech firms to streamline operations and concentrate resources on high-potential therapeutic areas. Overall, these developments illustrate a vibrant pharmaceutical and biotech landscape characterized by scientific innovation, strategic alliances, regulatory shifts, and technological integration—all aimed at advancing patient care and therapeutic efficacy in an increasingly complex global environment. As companies continue to navigate these challenges and opportunities, they are set to reshape the future of drug development with significant implications for patient outcomes worldwide.Support the show

Como os novos avanços da terapia radioligante, os desafios da comunicação científica na era digital e o foco no impacto clínico da IA transformam a prática médica? Neste episódio do Afya News, analisamos a decisão da FDA que ampliou o uso do Pluvicto (lutécio Lu-177) para estágios mais precoces do câncer de próstata metastático sensível à modulação hormonal, destacando a importância da seleção por PET-PSMA e do trabalho multidisciplinar. Discutimos também o artigo publicado na Nature Medicine pela Quality Health Information for All Commission sobre a necessidade de combater a desinformação para aprimorar a relação médico-paciente. Por fim, apresentamos no Radar o debate da American Medical Association com lideranças médicas abordando a integração segura e responsável da inteligência artificial nos fluxos de trabalho. O Afya News apresenta notícias da medicina com informação confiável e atualizada no seu tempo. Criado pela Afya, o maior hub de educação e soluções para a prática médica do Brasil, nosso propósito é transformar a saúde junto com quem tem a medicina como vocação.Fontes do episódio aqui:⁠https://portal.afya.com.br/podcasts/afya-news/12-08-2026Conteúdo 100% validado por equipe médica.Médico Responsável: Dr. Guilherme Rodrigues — CRM-RJ 1049461.

Anthony Fauci went to medical school, but never practiced medicine. Instead he moved to the dark side, where he became a bureaucrat's bureaucrat in an agency that Congress had no proper authority to create. In doing so, he lined his pocket - and his friends' pockets - with your tax money while killing millions.

Para precio y disponibilidad, vaya a este vínculo: https://amzn.to/4welLOV En este episodio Otto presenta unos audífonos de Anker que cancelan ronquidos y generan ruido blanco para dormir mejor, comparte su experiencia personal y dónde encontrar más detalles en sus redes. También conversan sobre agentes de inteligencia artificial que organizan viajes, reservan en gimnasios o gestionan turnos —y los problemas éticos y fallos que han permitido a usuarios manipular listas—, así como el impacto de estas herramientas en la vida diaria. Además, hablan del próximo iPhone 18, posibles colores y el nuevo programa de leasing de Apple, y de la aprobación por la FDA de audífonos de Samsung que ayudan a personas con problemas de audición a un costo más accesible. WWW.OTTOTECNOLOGIA.COM .

Trevor Ault has the latest on the devastating 7.4 magnitude earthquake that rocked Colombia – collapsing buildings, trapping people under rubble and killing over 100 people; Mary Bruce reports on the executive order Pres. Trump signed to limit childhood vaccines, calling for children to get vaccinated against 11 diseases instead of the 18 previously recommended by the CDC; Elizabeth Schulze has details on some of the country's biggest grocery stores recalling dozens of products with jalapeños over fears of a growing salmonella outbreak, which the FDA says has sickened 345 people across 27 states; and more on tonight's broadcast of World News Tonight with David Muir. Learn more about your ad choices. Visit podcastchoices.com/adchoices

────────────────────────────────────────[00:02:07]Partisan Split Attempt on Flock and Data Centers — Don't Abandon This Bipartisan Issue to the LeftNew York Sun calls it a leftist crusade; Politico frames it as a radical Democrat movement; if you oppose these because Democrats oppose them, you are serving the surveillance state.────────────────────────────────────────[00:22:37]Tyler Hudson Essay: "I Cannot Remember a Single Child Who Couldn't Speak" — Now It's One in 20 BoysA 22-year autism dad documents childhood in the 1970s; nobody he asks remembers a single nonverbal child; autism was one in 10,000 in 1983, now one in 20 among boys.────────────────────────────────────────[00:32:21]New Cholesterol Guidelines Would Make 100 Million Americans Patients — Disease Creation for a Drug MarketAHA lowered the LDL threshold to 100; a third of Americans now technically diseased; new drugs are ready; purpose is to create lifelong customers.────────────────────────────────────────[00:34:25]Trump's Childhood Vaccine Executive Order Is a Head Fake — States Set the Schedule, Not the PresidentHe signed an order to limit vaccines and split the MMR; states control the schedule; FDA just approved a new mRNA flu shot; virtue signaling with no teeth.────────────────────────────────────────[01:19:56]Dr. Shiva Won a TRO Against Massachusetts Officials for Government-Directed Twitter Censorship in 2020A federal judge barred the state from silencing Dr. Shiva — before Musk, before Twitter Files; Tucker Carlson and Glenn Greenwald refused to cover it.────────────────────────────────────────[01:25:24]Dr. Shiva Discovered the Weighted Race Feature in Election Machines — Trump Made Half a Billion Off That WorkThe feature multiplies one candidate's votes by a scalar; Shiva ran 3,000 audits; Lindell, Trump, and others hijacked the findings and monetized them.────────────────────────────────────────[01:30:32]48% of Americans Are Independent — Tucker Carlson and Andrew Yang Are There to Capture That Energy for the Swarm26% Democrat, 26% Republican, 48% independent nationally; the establishment creates fake independent movements to absorb people breaking from both parties.────────────────────────────────────────[01:36:45]Alex Jones Makes the Truth Unbelievable — Standard CIA TechniqueGives people the tagline without specifics so it sounds like nonsense; when a scientist raises the same issue it has to fight the parody Jones created.────────────────────────────────────────[01:38:24]Dr. Shiva Invited to PBS Senate Debate — Must Raise $250K by September 1stCollected 10,000 certified signatures; threshold added late; 60-70% there; shiva4senate.com/donate.────────────────────────────────────────[02:14:35]Zionism Is a Political Ideology Not a Religion — Like Brahminism It Justifies a Few Ruling Over the ManyFounded by an atheist; wraps politics in religious framing; AIPAC translates that into US policy; Jewish and Zionist are not the same. ──────────────────────────────────────── The Tennessee Farm mentioned in today's program can be seen at: https://www.zillow.com/homedetails/059-05700-Spring-Creek-Rd-Dandridge-TN-37725/439315766_zpid/For information email Roger at FiveRiversLand@ProtonMail.comMoney should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code “KNIGHT” For high quality made in America products go to HomeSteadProducts.shop and use promo code “Knight” for 10% off your purchases Find out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-show Or you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

────────────────────────────────────────[00:02:07]Partisan Split Attempt on Flock and Data Centers — Don't Abandon This Bipartisan Issue to the LeftNew York Sun calls it a leftist crusade; Politico frames it as a radical Democrat movement; if you oppose these because Democrats oppose them, you are serving the surveillance state.────────────────────────────────────────[00:22:37]Tyler Hudson Essay: "I Cannot Remember a Single Child Who Couldn't Speak" — Now It's One in 20 BoysA 22-year autism dad documents childhood in the 1970s; nobody he asks remembers a single nonverbal child; autism was one in 10,000 in 1983, now one in 20 among boys.────────────────────────────────────────[00:32:21]New Cholesterol Guidelines Would Make 100 Million Americans Patients — Disease Creation for a Drug MarketAHA lowered the LDL threshold to 100; a third of Americans now technically diseased; new drugs are ready; purpose is to create lifelong customers.────────────────────────────────────────[00:34:25]Trump's Childhood Vaccine Executive Order Is a Head Fake — States Set the Schedule, Not the PresidentHe signed an order to limit vaccines and split the MMR; states control the schedule; FDA just approved a new mRNA flu shot; virtue signaling with no teeth.────────────────────────────────────────[01:19:56]Dr. Shiva Won a TRO Against Massachusetts Officials for Government-Directed Twitter Censorship in 2020A federal judge barred the state from silencing Dr. Shiva — before Musk, before Twitter Files; Tucker Carlson and Glenn Greenwald refused to cover it.────────────────────────────────────────[01:25:24]Dr. Shiva Discovered the Weighted Race Feature in Election Machines — Trump Made Half a Billion Off That WorkThe feature multiplies one candidate's votes by a scalar; Shiva ran 3,000 audits; Lindell, Trump, and others hijacked the findings and monetized them.────────────────────────────────────────[01:30:32]48% of Americans Are Independent — Tucker Carlson and Andrew Yang Are There to Capture That Energy for the Swarm26% Democrat, 26% Republican, 48% independent nationally; the establishment creates fake independent movements to absorb people breaking from both parties.────────────────────────────────────────[01:36:45]Alex Jones Makes the Truth Unbelievable — Standard CIA TechniqueGives people the tagline without specifics so it sounds like nonsense; when a scientist raises the same issue it has to fight the parody Jones created.────────────────────────────────────────[01:38:24]Dr. Shiva Invited to PBS Senate Debate — Must Raise $250K by September 1stCollected 10,000 certified signatures; threshold added late; 60-70% there; shiva4senate.com/donate.────────────────────────────────────────[02:14:35]Zionism Is a Political Ideology Not a Religion — Like Brahminism It Justifies a Few Ruling Over the ManyFounded by an atheist; wraps politics in religious framing; AIPAC translates that into US policy; Jewish and Zionist are not the same. ──────────────────────────────────────── Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code “KNIGHT” For high quality made in America products go to HomeSteadProducts.shop and use promo code “Knight” for 10% off your purchases Find out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-show Or you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.

Why do so many companies struggle with cash flow at the exact moment they have their biggest opportunity in front of them? Today we're talking about the hidden financial challenges of growth, how businesses can prepare for larger opportunities, and why access to the right capital strategy can determine whether a company scales or stalls. Our guest today is Eric Rabinovich, Managing Director of X-Caliber GovCon Capital. Eric brings a rare perspective to this conversation, having worked as a government contractor, served as a federal contracting officer with the FDA, and now helping businesses access the capital they need to execute on major contracts. During the show we discuss: Why landing a major contract can create a cash-flow crisis even when it's one of the biggest growth opportunities for a business. How to bridge the award-to-payment gap when payroll, vendors, materials and other expenses have to be paid before the customer pays you. How contract-backed working capital works, including how lenders can evaluate unbilled obligated dollars to determine available capital. Why cash flow and profitability are two different conversations and why a profitable business can still run into serious financial trouble. Why waiting until you need capital can dramatically limit your options, and how proactive capital planning can put you in a stronger position. How to prepare your business for financing by maintaining accurate, reliable books and understanding your P&L and financial position. How to compare different financing options, including traditional bank lines of credit, invoice factoring, asset-based lending and contract-based working capital. How to choose capital based on your specific situation, rather than assuming one financing product is automatically the best option. Resources: https://x-calibercap.com/x-caliber-govcon-capital/

Low Value Mail is a live call-in show discussing current events, politics, conspiracies and much more.Every Monday night at 7pm ETSupport The Show:

Skin cancer is the most common cancer in America, yet millions of people never receive the annual skin exam doctors recommend. So what if your primary care physician could detect suspicious moles in seconds using AI?In this episode of the Miami Tech Pod, Maria sits down with Cody Simmons, Co-Founder and CEO of DermaSensor, the company behind America's first FDA-authorized, AI-powered skin cancer detection device.Cody shares the incredible eight-year journey from research project to commercialization — including miniaturizing a 30-pound laboratory machine into a handheld device, navigating the tough FDA approval process, raising venture capital, and building one of Miami's most promising medical technology companies.They also discuss:How DermaSensor works (and why it isn't just taking photos)Why primary care doctors miss up to half of melanomasThe realities of building a healthcare startup versus softwareThe future of AI in preventative healthcareMiami's evolution into a serious healthcare and technology hub

Devin: What is your superpower?Emily: So I think— I, I don't— it's hard for me to boil it down to just one, but I would simply say my superpower is really rooted in connecting dots. And so seeing things that others may not see because I'm able to put the dots together.Food as medicine can move from a hopeful idea to a scalable health care solution when the people closest to the problem build the system.That is the lesson I heard from Emily Brown, founder of Attane Health and now Chief Healthcare Officer at Sifter Solutions after Attane's acquisition. Emily's work began not with a business plan but with her daughter's diagnosis and a family grocery budget that suddenly could not keep up.“It all started with lived experience, my family's own personal experience with food insecurity and just the need to have specific foods to support my daughter's health,” Emily told me. “We were on WIC, SNAP. I'm actually a former Medicaid recipient.”That experience revealed a gap in health care that millions of families know too well. Doctors can diagnose food-related conditions but families are often left alone to figure out how to pay for and prepare the foods that could help them heal.Emily first responded by founding a nonprofit that helped get special dietary foods into food banks and pantries. Under her leadership, the organization launched one of the first food prescription programs in Kansas, serving clients who had prescription diet orders from physicians.Over time, Emily saw that charity alone could not solve the problem at national scale. Health care needed the tools, data and infrastructure to make food and nutrition care part of routine delivery.“I knew that technology was gonna be really important to scaling our work,” she said. “So I left the nonprofit, started what became Attane, really to develop the technology and the infrastructure to do food and nutrition care at scale.”Attane Health now works as the health care arm of Sifter Solutions, partnering with health plans, pharmacy benefits and health systems to expand access to nutrient-dense foods, education and measurable outcomes. Emily pointed to high-risk maternal health as one powerful example, where better nutrition can support mothers facing gestational diabetes or preeclampsia while helping reduce risks for babies.Her message is practical and hopeful. Food is not a side issue in health care. For millions of people living with chronic conditions, food is part of the standard of care. Emily is helping build the bridge so patients can actually access it.tl;dr:This episode shows how lived experience can spark scalable health care innovation.Emily Brown built Attane Health to make food and nutrition care accessible.Attane Health now grows through Sifter Solutions after a strategic acquisition.Emily explains why storytelling helps turn hidden health challenges into action.This article highlights practical ways to develop the superpower of connecting dots.How to Develop Connecting Dots As a SuperpowerEmily describes her superpower as “connecting dots” and “being able to tell that story.” She sees things others may miss because she can “put the dots together,” then frame the insight in a way that helps others act. She said, “The power of storytelling is really significant because we learn through stories, we connect through story.” That combination has helped her move from being a mother on Medicaid facing food insecurity to becoming a venture-backed founder building solutions for families like hers.Emily's superpower became visible when her daughter received a diagnosis that required a gluten-free diet. Overnight, Emily looked in her pantry and realized many of the foods her family relied on were no longer safe. Her grocery budget quadrupled while her resources shrank. Instead of accepting a system that paid only for clinic care, she began identifying every point of friction. That led her to start a nonprofit, create food prescription programs, advocate before federal agencies and eventually build Attane Health to integrate food and nutrition care into health care at scale.Frame your challenges as opportunities for growth, connection and innovation.Ask what is missing from the data before assuming the data tells the whole story.Look for the friction points hiding in plain sight and treat them as places to build solutions.Bring others with you by using stories from data, patients and partners.Be patient when building disruptive solutions because meaningful change often takes time.By following Emily's example and advice, you can make connecting dots a skill. With practice and effort, you could make it a superpower that enables you to do more good in the world.Remember, however, that research into success suggests that building on your own superpowers is more important than creating new ones or overcoming weaknesses. You do you!Guest ProfileEmily Brown (she/her):Founder of Attane Health, Chief Healthcare Officer at Sifter Solutions, Attane Health, Now a Sifter Solutions CompanyAbout Attane Health: To improve health through food and nutrition care by providing access to health foods, education, and actionable data.Website: attane-health.com, siftersolutions.comCompany Facebook Page: facebook.com/attanehealthBiographical Information: Emily is the Co-founder of Attane Health and Chief Healthcare Officer of Sifter Solutions, a digital health company in the “food is medicine” space. Rooted in lived experience, Emily leads a passionate team dedicated to changing health outcomes through harnessing the healing power of food.After experiencing first-hand, the challenges of managing chronic health conditions with limited resources, Emily founded Food Equality Initiative (FEI). Under her leadership the nonprofit grew to a 7-figure annual budget, supporting patients access to healthy food. Emily is a national patient advocate who has provided both oral and written testimony to the FDA and USDA. A member of the 2025 Child and Adult Core Set Annual Review Workgroup, Emily works to advance health equity in all pursuits.Her research interests include food systems, health disparities, and patient-centered approaches to care. Emily is a published co-author of several peer-reviewed articles with top research institutions in allergic disease. Emily believes in the power of patients and data to achieve greater health outcomes.Personal X/Twitter: @emilybrownspeak Personal Facebook Profile: facebook.com/emily.brown.37853Instagram: @emilybrownspeaksSupport Our SponsorsOur generous sponsors make our work possible, serving impact investors, social entrepreneurs, community builders and diverse founders. Today's advertisers include PurposeBuilt100™ Winners and supercrowd.tv. Learn more about advertising with us here.Max-Impact Members(We're grateful for every one of these community champions who make this work possible.)Brian Christie, Brainsy | Cameron Neil, Lend For Good | Carol Fineagan, Independent Consultant | Eric Coury, Arthia AI | John Berlet, CORE Tax Deeds, LLC. | Justin Starbird, The Aebli Group | Ken Steele, Rotarian | Lory Moore, Lory Moore Law | Marcia Brinton, High Desert Gear | Mark Grimes, Networked Enterprise Development | Mike Babbit | Coledger Solutions | Mike Green, Envirosult | Nick Degnan, Unlimit Ventures | Paul Lovejoy, Stakeholder Enterprise | Pearl Wright, Global Changemaker | Scott Thorpe, Philanthropist | Sharon Samjitsingh, Health Care Originals | Add Your Name HereUpcoming SuperCrowd Event CalendarIf a location is not noted, the events below are virtual.Join the SuperCrowd Impact League! You can be recognized for making impact investments via Reg CF. See how your activity compares to your peers. It's free. Win valuable prizes. Start now!SuperCrowd Impact Member Networking Session: Impact (and, of course, Max-Impact) Members of the SuperCrowd are invited to a private networking session on August 11th at 8:00 PM ET/5:00 PM PT. Mark your calendar. We'll send private emails to Impact Members with registration details. Upgrade to Impact Membership today!SuperCrowdHour, August 19, 2026, at 12:00 PM Eastern. Devin Thorpe, CEO and Founder of The Super Crowd, Inc., will lead a session on “How to Make Money As an Impact Investor Starting with $10.” Drawing on his experience as a former investment banker, impact investor, and crowdfunding expert, Devin will demonstrate how anyone can begin building wealth while investing in companies that create positive social and environmental impact—even with as little as $10. In this session, he'll explore how impact crowdfunding has opened investment opportunities to everyday investors, explain how to identify promising mission-driven companies, and share practical strategies for building a diversified portfolio over time. Attendees will learn how to get started with limited capital, manage risk, evaluate investment opportunities, and avoid common mistakes new investors make. Whether you're completely new to investing or looking for an affordable way to expand your impact investing portfolio, this SuperCrowdHour will provide actionable insights to help you invest with purpose, build long-term wealth, and make a meaningful difference. Register now!SuperCrowd26 featuring PurposeBuilt100™: This August 25–27, founders, investors, and ecosystem leaders will gather for a three-day, broadcast-quality global experience focused on disciplined capital formation, regulated investment crowdfunding, and purpose-driven growth. We're bringing together leading voices in impact investing, compliance, digital marketing, and circular economy innovation to deliver practical frameworks, real-world case studies, and actionable strategies. The event culminates in the PurposeBuilt100™ Showcase, recognizing 100 of the fastest-growing purpose-driven companies in the U.S. Register now to secure your seat and get all the details. August 25–27, streaming worldwide.Community Event CalendarSuccessful Funding with Karl Dakin, Tuesdays at 10:00 AM ET - Click on Events.Register Now! Join Investors Circle and DAF Commons on August 19, 2026, from 12:00–1:30 PM ET for an insightful conversation on how Donor Advised Funds (DAFs) can become a powerful engine for impact investing. Hear from leaders at ImpactAssets, Impact Charitable, and RSF – Regenerative Social Finance as they explore ways to put charitable capital to work creating measurable impact today. Learn about emerging opportunities for DAF holders to participate in pooled impact investments and climate-focused funding initiatives.Register Now! October 20th and 21st will be the Crowdfunding Professional Association Regulated Investment Crowdfunding Summit for 2026. This is the event of the year for everyone in the crowdfunding ecosystem.If you would like to submit an event for us to share with the 10,000+ changemakers, investors and entrepreneurs who are members of the SuperCrowd, click here.Manage the volume of emails you receive from us by clicking here.We share educational information—not investment advice. Some links may generate compensation. See our full disclosure.We use AI to help us write compelling recaps of each episode. Get full access to Superpowers for Good at www.superpowers4good.com/subscribe

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Catherine Gratz Griffin Lake Forest Hospital, joins John Williams to talk about the FDA approving a new mRNA flu vaccine.

Brittney Miller is President of Manchester Farms, America's first quail farm. What started over 40 years ago as a backyard hobby has grown into a nationally recognized, family-owned business that produces more than 80,000 quail weekly, raising them responsibly, without antibiotics or hormones, and shipping premium products to chefs, retailers, and home cooks across the country. Brittney's story is about more than farming: it is about stewardship, innovation, and family values. She combines her passion for sustainable agriculture with modern food safety standards. Her SQF Level 2 certified, HACCP-compliant farm sets the benchmark for quality in specialty poultry. In this episode of Food Safety Matters, we speak with Brittney [28:27] about: The history of Manchester Farms, America's first quail farm, and how the Miller family built a vertically integrated specialty poultry operation How food safety considerations for quail production compare with those for more conventional poultry, including unique challenges and operational considerations What SQF Level 2 certification and a HACCP program look like in practice within a specialty poultry production environment How HACCP guides day-to-day operations, and how it has evolved as production expands and processes change News and Resources News Researchers Propose Listeria Biofilm Colonization Hypothesis to Explain Persistence in Food Processing Plants [7:05] Researchers Identify Plastic Food Contact Material Properties, Background Microbes that Influence Listeria Biofilm Persistence [8:52] Research Collaboration Produces Guidance for Controlling Spore-Forming Bacteria in Plant-Based Beverage Ingredients [17:22] FDA to Centralize Administrative Functions, Generalize Inspectors [21:00] We Want to Hear from You! Please send us your questions and suggestions to podcast@food-safety.com

Pressure is on FDA, policymakers and academic centers in the U.S. to respond to challenges from China, Australia, and beyond to run first in human trials faster and more efficiently. On the latest BioCentury This Week podcast, BioCentury's analysts discuss how stakeholders in the U.S. are responding to the challenge.The analysts also discuss the next frontiers of federated learning in drug discovery and the latest crop of biotech IPOs on NASDAQ, which raised over $1.2B in strong IPO run last week.View full story: https://www.biocentury.com/article/660433#ClinicalTrials #BiopharmaPolicy #DrugDevelopment #BiotechIPO #FederatedLearning00:00- Introduction01:15 - Academic Centers10:42 - Policy Picture15:48 - Grand Rounds Europe Highlights18:01 - Federated Learning28:15 - NASDAQ IPOsTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Send us Fan MailA 27 year old woman went to a longevity clinic in the Bronx for an NAD IV drip. Minutes later she was in cardiac arrest. She died a few hours after that. The person who ran the clinic held a medical license from the Dominican Republic, not the United States.Dr. Kevin White talks with Dr. Matt Kaeberlein, a researcher who studies why and how we age, about what that story actually tells us. His answer isn't really about NAD. It's about certainty. Kaeberlein has never seen evidence that NAD infusions help anyone, and the field's founding claim, that NAD declines with age and needs replacing, is now being questioned by the same scientists who study it. Clinics keep selling it with total confidence anyway.That same pattern shows up everywhere they go in this conversation. Kaeberlein now chairs Montana's expanded Right To Try review board, which lets biotech companies test experimental therapies on real patients once they clear a phase one safety bar, outside the usual FDA process. He explains why that could produce safety data the field has never had, and why he'd reject any therapy pitched without a real scientific rationale behind it, no matter how confidently it's sold."You don't want to listen to the people who are telling you with a hundred percent certainty, do this. And by the way, you know, buy my longevity latte."                                                    — Matt KaeberleinThey also compare LinAge2, a biological age calculator built from standard bloodwork with decades of mortality data behind it, to the consumer epigenetic age tests sold directly to the public. Kaeberlein's problem with the popular tests has nothing to do with the underlying science. It's that nobody selling them will publish the error bars, so a 20 year gap on your result could mean everything or nothing. You can't run statistics on a number you're not allowed to check.Along the way they cover why rapamycin, the drug most associated with Kaeberlein's name, might not even be his top pick anymore. A company spun out of his lab, Aura Biomedical, has found longevity molecules that also protect against radiation damage. And a new epigenetic instability test from Irena Conboy's company, Generation Lab, measures something closer to biological chaos than biological age.Follow The Daily Apple and leave a review to help more people find the show. Instagram: @KevinWhiteMDYouTube: @KevinWhiteMD Prime Health Associates

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Catherine Gratz Griffin Lake Forest Hospital, joins John Williams to talk about the FDA approving a new mRNA flu vaccine.

Your AirPods Pro can run a real hearing test. FDA approved and free. Plus, AI generated country band, Breaking Rust, just hit #1 on Billboard's digital sales chart. We talk about what's next for chatbot music. Learn more about your ad choices. Visit megaphone.fm/adchoices

We break down T1's shocking call to bench Oner for rookie Jungler Painter in an LCK showdown against Hanwha Life Esports.   LFN Premium: Submit topics through private Discord channels, go ad-free across all 16 LFN shows on every podcast platform, and help keep LFN free. Sign up at https://www.lastfreenation.com   Hims: Weight Loss by Hims offers access to FDA-approved GLP-1 options like the Wegovy pill and pen to help you lose weight and keep it off, no insurance necessary. Visit https://hims.com/powerspike   DripDrop: Doctor-developed, science-based fast hydration with three times the electrolytes of leading sports drinks, trusted by pro teams and perfect for staying ahead all summer long. Use code LFN at https://dripdrop.com for 20% off your first order Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

A healthy 27-year-old walked into a Bronx wellness center for an NAD+ "longevity infusion" — and was dead within the hour. The man holding the needle wasn't licensed to practice medicine anywhere in the US. Robert Lufkin MD breaks down the Elizabeth Baron case: what actually happened, what NAD+ can and can't do based on the real evidence, why the billion-dollar med spa industry operates like the Wild West, and the three-license checklist that can protect you before anyone puts a needle in your arm.Chapters:00:00 — Introduction: Death After an Anti-Aging IV Drip00:44 — What Happened in the Bronx: The Elizabeth Baron Case01:58 — What's Actually in the Bag: NAD+ Explained02:56 — No Randomized Trial Evidence for IV NAD+03:38 — The Wild West: Inside the Unregulated Med Spa Boom04:02 — A Pattern of Med Spa Deaths and Injuries04:54 — The Three Licenses: Person, Building, Bottle06:19 — The Honest Caveat: Cause of Death Still Pending07:17 — The Takeaway: Fundamentals Beat the DripKey takeaways:NAD+ is real biology — a coenzyme central to energy production and DNA repair — but no randomized trial has ever shown an IV NAD+ drip slows aging in humans.IV NAD+ is legal yet not FDA approved for any specific application, and the marketing has sprinted far ahead of the evidence.An IV bypasses every natural checkpoint in your body. Treat it like surgery on your blood.Before any injection or infusion, verify three licenses: the person, the building, and the bottle. If a clinic can't answer instantly, walk out.The fundamentals that actually move healthspan — muscle, metabolic health, sleep, blood pressure, blood sugar — cost almost nothing and have mountains of evidence.Sources & reporting:NY Daily News — Bronx clinic death and arrestNY Post — arraignment coverageArina Cadariu MD, MPH — "Nobody Is Counting"NY Post — inside the unregulated med spa industryNewser — case roundupCBS News New York — the three licenses

All Links Here: ⁠⁠https://hunterwilliamshealth.com/links⁠Melanotan 1 and Melanotan 2 are the two peptides people ask me about every summer. So I put together the full masterclass on both.I combined them because you cannot really talk about one without the other. They came out of the same research program at the University of Arizona. But they hit different receptors, and that changes everything about how you use them.We get into how the melanocortin system works and why sunlight is still required. I walk through the eumelanin shift, which is the pigment that actually protects you. Melanotan 1 is FDA approved for a rare light sensitivity condition. Melanotan 2 has three small studies from the 90s and a lot of gray market use.I cover my dosing tiers, dosing by skin type, cycling patterns, and how to time a cycle around a beach trip or a wedding. I also cover what to stack it with and what to never run alongside. Then the side effects nobody warns you about. Nausea, flushing, darkening moles, and priapism are all real.I talk honestly about the skin cancer question. Nobody knows for sure, and I say that.My verdict is at the end. For most people it is not the one they expect.

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Catherine Gratz Griffin Lake Forest Hospital, joins John Williams to talk about the FDA approving a new mRNA flu vaccine.

A bitter feud has erupted between Candace Owens and conservative commentator Andrew Wilson over Owens' claims about Charlie Kirk's assassination, with Wilson publicly offering $300,000 for a debate that Owens has countered with a $500,000 proposal.  As Jimmy explains, central to the dispute are leaked private messages from Kirk expressing frustration with pro-Israel donors, which Owens released, while Wilson argues she has presented no evidence for her allegations against Israel, TPUSA, and Erika Kirk's potential involvement.  Wilson has also faced backlash for his debate tactics after he was caught on video contradicting himself about what the leaked texts actually said. Even Joe Rogan pointed out to Wilson that Erika Kirk's behavior since her husband's death has been "insane." Both Owens and Wilson are currently negotiating the debate's location and terms, with no formal date yet set. Plus segments on Tucker Carlson, Marjorie Taylor Greene, Thomas Massie and others possibly forming a new political party and the FDA's approval of a new mRNA flu vaccine. Also featuring Stef Zamorano, Kurt Metzger and Dr. Angus Dalgleish!

P.M. Edition for Aug. 10. The FDA has laid out new rules intended to make the food system more transparent, part of an overhaul promised by Health Secretary Robert F. Kennedy Jr. WSJ reporter Liz Essley Whyte discusses how the new rules would work and why guidelines for ultraprocessed foods didn't come today. Plus, as Iran strengthens its demands in negotiations to reopen the Strait of Hormuz, Gulf states have begun accepting a new reality: that Tehran will control the strait for the foreseeable future. We hear from WSJ Middle East correspondent Benoit Faucon about what they are doing about it. And more than 70 people have been killed in a 7.4 magnitude earthquake in Colombia. Alex Ossola hosts. Sign up for the WSJ's free What's News newsletter. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

(00:00:00) 228: Foods That Can Kill You; and What You Can't Do About IT! (00:00:11) Welcome to the Itchy and Bitchy Podcast (00:00:42) Doc Itchy Medical Pets Supplements (00:01:02) The Dirty Dozen: Pesticide Contaminated Produce (00:07:07) The Pathogen Problem: Foodborne Illnesses on the Rise (00:15:28) The Controversy: What to Do About Contaminated Food (00:25:56) Practical Steps to Reduce Food Contamination Risk (00:31:32) Closing Remarks and Future Episode Preview (00:31:39) Doc Itchy Medical Pets Supplements (Repeat) Cyclospora and Cyclosporosis is infection tens of thousands of AMERICANS causing some deaths. More and More food pathogens are affecting us through contaminated food items and they are making us sick.Add to that the unavoidable contamination of our food with chemicals and pesticides and we are experience a food crisis.Even if you try to eat "Healthy" food items, these may be inthe "dirty Doozen" most contaminated foods available in stores.The Docs discuss the problem, the pathogens, and the pesticides and how we came to find ourselves in this crappy toxic and dangerous time. The Docs will also discuss - argue over what you can or can't do the avoid or prevent your exposure to the pathogens and poisons on and in your foods.Become a supporter of this podcast: https://www.spreaker.com/podcast/itchy-and-bitchy-podcast--4303608/support.Itchy & Bitchy: Have you felt dismissed, misdiagnosed, or gaslit by a broken medical system.  From gut health, hormones, autoimmune disease, chronic pain, holistic health, and alternative medicine ... medical gaslighting, patient advocacy , or misdiagnosis we'll call that too.  For chronic illness warriors, self-advocacy seekers: WE OFFER  No BS 

In this episode, I unpack my pregnancy symptoms and emotions from weeks 28-31 and the whiplash of being so ready to not be pregnant anymore while simultaneously freaking out that there's about to be another human in this house!! I get into nesting in the middle of a house renovation, the Braxton Hicks and charley horses I've been experiencing, and how food noise has crept back in during pregnancy. I also open up about my heightened emotions right now and how toxically I miss the way my body used to look.Key Takeaway / Points:Nesting while renovating: purging, hunting down baby gear, and feeling logistically unprepared for the thirdBraxton Hicks, charley horses, alien-style kicks, and the sounds I now make just getting out of a chairFood noise returning during pregnancy and why it feels different this timeLack of sleep, heightened emotions, and my honest feelings about not finding out the sexSummer FOMO with my boys at the beach while pregnantThis episode is sponsored by Natural Cycles, the company behind the first FDA-cleared, hormone-free, and non-invasive birth control app that helps prevent or plan pregnancy naturally. Use code CAMERON at naturalcycles.app/Cameron for 15% off an annual subscription + a FREE NC° Band. The NC° app is for 18+ and does not protect against STIs. Always read and follow the instructions for use.Visit ⁠Quiet Your Mind⁠ to shop Quiet Your Mind x WTF Is Happening To My Body edition.Follow me:Instagram: @cameronoaksrogersSubstack: Fill Your CupWebsite: cameronoaksrogers.comTikTok: @cameronoaksrogersYouTube: Cameron Rogers

The latest on the strongest earthquake recorded in Colombia in the last decade. President Donald Trump signed an executive order changing the childhood vaccine schedule. The FDA announced a plan to close loopholes in food additives. Russia's calling today's drone strike by Ukraine the deadliest attack inside the country in more than two years. Plus, the long-awaited trial for the murder of rapper Tupac Shakur kicks off with jury selection. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Peptides are everywhere right now—from social media and podcasts to conversations about weight loss, longevity, energy, and overall wellness. But what exactly are peptides, and how do they work in the body? In this episode of Between Two White Coats, Dr. Michelle Plaster and Nurse Practitioner Amber Foster kick off a three-part series on peptides by breaking down the basics. They explain what peptides are, how they interact with the body, and why they believe they can be a valuable tool in a more root-cause and personalized approach to health and wellness. They also discuss the importance of medical supervision, how to think about FDA approval, the role of reputable compounding pharmacies, why peptides may need to be cycled, and who should—and should not—consider peptide therapy.If you've been hearing about peptides and wondering whether they're safe, effective, or right for you, this episode is a great place to start!Listen in as we take a closer look at the science, safety, and potential of peptides—and why they're becoming such an exciting tool in modern health and wellness. Hosted on Acast. See acast.com/privacy for more information.

What if the peptide you just ordered online isn't wrong — it's just wrong for you? In Episode 2 of our peptides series, clinical pharmacist Dr. Melissa Jones takes us inside the actual decision-making process providers use to match a peptide to a patient, and why skipping that process is how people end up wasting money, or worse, hurting themselves. Host Jamie Preston and Dr. Jones dig into the real science: what a peptide is, how peptides signal the body, and why a healthy foundation — hormones and gut health — has to come before any peptide is even considered. From there, they cover the wide menu of options (tissue repair, skin and hair, sexual health, growth hormone support, metabolic health, sleep and stress) and what it actually means to “stack” or “cycle” peptides responsibly. In this episode, you'll hear: Why there isn't — and won't be — one peptide that does it all, and what that means for how providers build a plan How stacking and cycling actually work, and where cost becomes a real factor in the decision The difference between FDA-approved peptide uses (like Tesamorelin for visceral fat) and the anecdotal dosing happening across the wellness world The real danger in reconstituting and self-dosing peptides ordered online, explained in plain terms What responsible, supervised GLP-1 (Mounjaro, Ozempic, tirzepatide) therapy looks like — and what goes wrong with compounded, unregulated versions The specific list of patients who should avoid peptides or use extra caution, and why providers need to know it cold If you've ever wondered whether a peptide could actually help you — or wondered what your provider is really weighing before saying yes — this episode gives you the real answer, not the Instagram version. www.YourHealth.Org